(Q30771011)

26 June 2017

title

A fully human antibody neutralising biologically active human TGFbeta2 for use in therapy (English)

1 reference

26 June 2017

1 reference

Thompson JE

1

1 reference

26 June 2017

Vaughan TJ

2

1 reference

26 June 2017

Williams AJ

3

1 reference

26 June 2017

Wilton J

4

1 reference

26 June 2017

Johnson KS

5

1 reference

26 June 2017

Bacon L

6

1 reference

26 June 2017

Green JA

7

1 reference

26 June 2017

Field R

8

1 reference

26 June 2017

Ruddock S

9

1 reference

26 June 2017

Martins M

10

1 reference

26 June 2017

Pope AR

11

1 reference

26 June 2017

Tempest PR

12

1 reference

26 June 2017

Jackson RH

13

1 reference

26 June 2017

publication date

1 July 1999

1 reference

Journal of Immunological Methods

26 June 2017

published in

1 reference

26 June 2017

volume

227

1 reference

26 June 2017

issue

1-2

1 reference

26 June 2017

page(s)

17-29

1 reference

Transforming growth factor-beta: the breaking open of a black box.

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

A transforming growth factor beta 2 (TGF-beta 2)-like immunosuppressive factor in amniotic fluid and localization of TGF-beta 2 mRNA in the pregnant uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Transforming growth factor beta in tissue fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Targeting TGF-beta for treatment of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

First genomic sequence of a human Ig variable lambda gene belonging to subgroup III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Calculation of protein extinction coefficients from amino acid sequence data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Structural motifs involved in human IgG antibody effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Human anti-self antibodies with high specificity from phage display libraries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Isolation of high affinity human antibodies directly from large synthetic repertoires.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Selection of phage antibodies by binding affinity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Transforming growth factor beta2 in the vitreous in proliferative diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Cell adhesion protein receptors as targets for transforming growth factor-beta action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Transforming growth factor-beta in human aqueous humor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-beta2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Cloning and expression of human V-genes derived from phage display libraries as fully assembled human anti-TNF alpha monoclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

By-passing immunization. Human antibodies from V-gene libraries displayed on phage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

By-passing immunization: building high affinity human antibodies by chain shuffling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

The transforming growth factor-beta family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Selection and rapid purification of murine antibody fragments that bind a transition-state analog by phage display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

TGF-beta3 stimulates and regulates collagen synthesis through TGF-beta1-dependent and independent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Immunologic tolerance: collaboration between antigen and lymphokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Transforming growth factor beta s and wound healing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Generation of a panel of related human scFv antibodies with high affinities for human CEA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Transforming growth factor beta 2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid and vitreous of the monkey eye

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Binding affinity of transforming growth factor-beta for its type II receptor is determined by the C-terminal region of the molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

A novel, sensitive bioassay for transforming growth factor beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Type beta transforming growth factor: a bifunctional regulator of cellular growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

An unusual feature revealed by the crystal structure at 2.2 A resolution of human transforming growth factor-beta 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Human antibodies by design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Cloning and sequencing of human immunoglobulin V lambda gene segments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900060-5

10.1016/S0022-1759(99)00060-5

7 January 2021

Identifiers

DOI

1 reference

26 June 2017

1 reference